N/A N=39 Glucocorticoids and Bone in Graves' Ophthalmopathy
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
Phase 4 N=200 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
Postoperative Complications
Primary: Serum Blood Glucose Concentrations — 101; 137; 140; 141 mg/dl
Phase 1 N=18 Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
Glucocorticoids Toxicity · Glucose Intolerance
Primary: White Blood Cell Counts — 5.26; 6.99 x10^3 cells/mL
Phase 4 N=66 Exploring the Effects of Corticosteroids on the Human Hippocampus
Hydrocortisone · Depression · Healthy Volunteers
Primary: Hippocampal Subfield Activation (Left Hemisphere) — -0.35; 0.03; -0.08; -0.07 Z-Score
N/A N=10 Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Pre-diabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
Phase 4 N=54 Reversing Corticosteroid Induced Memory Impairment
Memory Impairment
Primary: The Rey Auditory Verbal Learning Test (RAVLT) — 45.741; 43.286 T Score
Early Phase 1 N=41 Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematous (SLE)
Primary: Number of SLE Patients That Were Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 20; 20; 20; 20 Participants
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Phase 2 N=25 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Phase 4 N=72 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Hyperglycemia
Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Phase 3 N=164 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Phase 4 N=22 Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
Ocular Hypertension · Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 14.7; 14.8 mmHg
Phase 1 N=25 Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids
Normal Physiology
Primary: Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 5; 20 Participants
Phase 4 N=12 Short Course Glucocorticoid Treatment for PTSD
Post-traumatic Stress Disorder
Primary: Change in Clinician-Administered PTSD Scale (CAPS) — 96.0; 90.7; 66.3; 86.2 score on a scale
N/A N=77 Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Congenital Heart Disease · Disorder of Fetus or Newborn
Primary: Primary Endpoint: Number of Participants With Low Cardiac Output Syndrome (LCOS) or Death at 36 Hours From Admission to the Intensive Care Unit (ICU) After Surgery…
Phase 4 N=30 Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy
Asthma · Rheumatic Disease
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 44.8; 44.1 words
Phase 4 N=5 Prednisolone Pharmacokinetics in Severe Asthma
Asthma
Primary: Serum Prednisolone Levels Over 24 Hours — 800; 700; NA nmol/l
Phase 2 N=24 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 13 Participants
Phase 3 N=428 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Osteoporosis
Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001
N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Phase 4 N=92 Ideal Steroids for Asthma Treatment in the PICU
Asthma Childhood
Primary: Length of Stay — 2.9; 2.9 days — p=0.632
Phase 2 N=28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Atopic Dermatitis
Primary: The Number of Patients in the Study With HPA Axis Suppression — 8; 9 Participants
Phase 2 N=16 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
N/A N=62 Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD
Posttraumatic Stress Disorder
Primary: PTSD Checklist (PCL). A Self-report, Face Valid Measure of PTSD Symptoms Over a 1 Week Time Period — 55.76; 54.83; 50.14; 51.57 units on a scale
N/A N=20 Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
Asthma
Primary: Airway Blood Flow (Qaw) — 22.3; 29.4; 34.1; 28.2 percentage of change from baseline
Phase 4 N=451 The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study
RheumatoId Arthritis
Primary: Signs and Symptoms: Mean DAS28 Post Baseline — 3.26; 3.62; 3.06; 3.42 score on a scale — p=<0.0001